The Discounted Cash Flow (DCF) valuation of Innate Pharma SA (IPH.PA) is (18.32) EUR. With the latest stock price at 1.53 EUR, the upside of Innate Pharma SA based on DCF is -1300.4%.
Based on the latest price of 1.53 EUR and our DCF valuation, Innate Pharma SA (IPH.PA) is a sell. selling IPH.PA stocks now will result in a potential gain of 1300.4%.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| WACC / Discount Rate | 5.0% - 7.5% | 6.3% |
| Long-term Growth Rate | 3.0% - 4.8% | 3.9% |
| Fair Price | (165.53) - (10.13) | (18.32) |
| Upside | -10947.6% - -763.5% | -1300.4% |